Work

Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease

Year: 2025

Type: article

Abstract: Purpose: To report magnetic resonance imaging (MRI) extraocular muscle (EOM) volume analysis in a patient with thyroid eye disease (TED) who was treated with two full courses of teprotumumab. Observations: An 84-year-old man with TED received two full courses (16/16 infusions) of teprotumumab. At the initial presentation, he had decreased visual acuity, proptosis, and diplopia. Imaging at this time illustrated enlarged EOMs, predominantly on the left side. After his first course of teprotumumab, his symptoms improved. However, he experienced disease reactivation 7 months later. A follow-up MRI revealed reduced EOM volume compared to baseline, though the patient reported recurrent symptoms. A second course of teprotumumab (8/8 infusions) was initiated, leading to clinical improvement. Six months after completion of his second teprotumumab course, a third MRI showed further reduction in EOM volumes compared to both baseline and pre-retreatment imaging. Conclusion: This case demonstrates the potential for continued radiographic and clinical improvement in TED patients after retreatment with teprotumumab. Further studies may clarify the role of EOM volume as a marker for treatment efficacy.

Source: American Journal of Ophthalmology Case Reports

DOI: 10.1016/j.ajoc.2025.102490

Authors: Hanna Richkind, Marissa K. Shoji, Megan Routzong, David Granet, Don O. Kikkawa, Jolene C. Rudell

Institutions: University of California San Diego, Sanford Consortium for Regenerative Medicine

Language: English

Topic: Ophthalmology and Eye Disorders

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,590